# Patent term extension scaled to proven survival gain

Source: https://onco.cc/ideas/idea-fund-value-based-patent-extension/  
OnCo record `idea-fund-value-based-patent-extension` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A drug that adds years of life would earn extra years of market protection; one that adds a few weeks would earn none. Extensions would be lost if the promised benefit is not confirmed.

## Summary

Supplementary protection or regulatory exclusivity would be granted in proportion to demonstrated overall survival or cure-rate gain over the best prior standard in a randomised trial (for example one additional year of exclusivity per six months of median overall survival gain, capped at five years, with bonuses for curative-intent settings). Approvals on surrogate endpoints receive provisional extension that is confirmed or revoked when survival data mature. Regulators already collect the necessary data; the change is to the reward, not the evidence standard.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Linking exclusivity to survival gain shifts industry portfolios: within a decade the share of pivotal trials with overall survival as a primary or co-primary endpoint rises substantially, and the average survival gain of approved drugs increases relative to the prior decade.
- Rationale: Exclusivity is the main lever of pharmaceutical reward and is currently flat with respect to benefit; paediatric exclusivity extensions show that firms respond strongly to even six months of added protection. Value-based rewards are the explicit goal of ESMO-MCBS and ASCO value frameworks, which are advisory today.
- Proposed test: Use economic modelling with historical approvals to calibrate the schedule, then run a legislated pilot in one jurisdiction for new oncology approvals over five years, tracking endpoint choice and benefit magnitude of filings.
- Maturity: speculative
- Actor: policy

## Sources

- Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022): https://doi.org/10.1038/d41573-022-00030-4

## Connected records

- ideas: [A billion-dollar prize for the first durable cure of a lethal metastatic cancer](https://onco.cc/ideas/idea-fund-cure-prize/), [Extra exclusivity for sponsors who run treatment-duration and de-escalation trials](https://onco.cc/ideas/idea-fund-duration-trial-exclusivity/), [Launch prices indexed to the ESMO benefit scale, revisited when survival matures](https://onco.cc/ideas/idea-fund-mcbs-linked-pricing/), [Shorter exclusivity for later-in-class drugs without added benefit](https://onco.cc/ideas/idea-fund-benefit-indexed-exclusivity/), [Transferable priority vouchers for first-in-class drugs, with price conditions](https://onco.cc/ideas/idea-fund-conditional-transferable-voucher/)
- terms: [Accelerated approval](https://onco.cc/terms/accelerated-approval/), [Overall survival (OS)](https://onco.cc/terms/os/), [Progression-free survival (PFS)](https://onco.cc/terms/pfs/)
- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Trial design, endpoints and cost](https://onco.cc/bottlenecks/b-trial-design/)
- key papers: [Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape](https://onco.cc/key-papers/paper-upadhaya-nat-rev-drug-discov/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-value-based-patent-extension.json